In the United Kingdom, approximately 50,000–60,000 patients access medical cannabis through over 30 regulated telemedicine platforms, with projections estimating 80,000 by the end of 2025.
Operating within a private, strictly governed framework, these patients benefit from legal recognition and access to pharmaceutical-grade products, including dried flower, oils, and edibles. However, high treatment costs exclude many, particularly those with chronic conditions.
South Africa’s 2018 Constitutional Court ruling decriminalized private cannabis use, yet the medical cannabis sector remains underdeveloped. The South African Health Products Regulatory Authority (SAHPRA) administers the Section 21 process, a cumbersome, doctor-initiated pathway for unregistered medicines.
The absence of licensed dispensaries, telemedicine platforms, and a national training pathway for prescribers forces patients to navigate a complex legal process or resort to unregulated sources, compromising safety and dignity. Unlike the UK’s private ecosystem, South Africa’s government has not delivered on promises of a public solution, reflecting a policy failure.
In the UK, telemedicine platforms provide stigma-free consultations, allowing patients with chronic pain, cancer, anxiety, or epilepsy to access care without fear of judgment. Medical aid recognition further legitimizes treatment, enabling pharmacy collections rather than backroom transactions. In South Africa, the Section 21 process lacks structure, clarity, or urgency. Patients face high costs and legal uncertainty, denying them dignity and choice. Stigma-free access is not just convenient—it restores a patient’s right to heal without hiding. 3
South Africa’s favourable climate, fertile soil, and agricultural expertise give us a significant advantage. Over 1,100 hemp cultivation permits have been issued since 2021, and companies like SafriCanna position South Africa as a premium exporter of EU-GMP certified cannabis. Yet, patients cannot access locally grown products due to the absence of a domestic distribution framework. Instead, we import cannabis from countries less suited to cultivation—an economic and ethical absurdity.
UK prescribing doctors benefit from specialist training and indemnity cover within a supportive ecosystem. In South Africa, prescribers face legal uncertainties and lack institutional support, with no standardized national training. Synergy Wellness, launched the Synergy Wellness Academy in 2024, an online platform training healthcare professionals on the endocannabinoid system, clinical prescribing principles, and SAHPRA Section 21 compliance processes.
Their certification program is a leading structured, compliance-focused pathway for South African physicians, requiring doctors to submit credentials, complete mandatory training, pass a certification exam, and receive ongoing regulatory support. While other programs, such as those by the Cannabis Institute and Cheeba Cannabis Academy, offer cannabis education, Synergy’s initiative is uniquely tailored to physicians navigating Section 21 requirements. However, it cannot substitute for a national framework.
The UK’s medical cannabis market, projected to exceed £300 million in 2025, illustrates the economic potential of a well-regulated system. South Africa could rival this, with estimates suggesting a $1.7 billion contribution to the African cannabis market. Yet, regulatory delays lead to farm closures, lost jobs, and eroded trust. The exclusion of legacy growers, traditional healers, and township entrepreneurs from reform processes perpetuates economic extraction by foreign firms, sidelining local innovators who understand the plant’s cultural and economic power.
South Africa’s delays are a choice, not a necessity. The UK built a functional system in under a decade, while we remain trapped in bureaucratic quicksand. Patients suffer, farms close, and opportunities vanish as we export cannabis overseas while denying local access. The state’s reliance on foreign consultants, ignoring local expertise, further disconnects policy from reality.
No one seems to know who the government consults for reform—it is certainly not patients, growers, or traditional healers.
South Africa cannot afford further delays. We don’t need promises; we need action. To build a just, inclusive, and medically credible cannabis future, South Africa must implement the following reforms with urgency:
• Establish a National Registry: Create a centralized, secure database for medical cannabis patients and prescribers, managed by SAHPRA or a designated authority. This registry would streamline access by tracking patient eligibility, prescribing patterns, and treatment outcomes, ensuring data-driven policy adjustments. It should protect patient privacy while providing real-time insights into demand and efficacy, enabling scalability. For example, the UK’s registry systems allow regulators to monitor usage trends, which informs resource allocation and clinician training needs.
• Develop a Public Product Database: Publish a transparent, accessible list of approved cannabis products, categorized by Section 21 status, SAHPRA registration, or clinical trial involvement. This database should detail product specifications (e.g., THC/CBD ratios, delivery methods), approved indications, and sourcing information. By providing clarity on available products, patients and clinicians can make informed decisions, reducing reliance on unregulated markets. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) maintains similar databases, enhancing trust and accessibility.
• Implement Dispensary and Telemedicine Frameworks: Model these on UK practices, where over 30 telemedicine platforms and private clinics provide efficient, stigma-free access. South Africa should license dispensaries under strict Good Pharmacy Practice (GPP) standards and integrate telemedicine to reach rural and underserved areas. This would reduce the burden on patients navigating the Section 21 process and eliminate reliance on costly imports. Regulated pilot projects in provinces like Western Cape or Gauteng could advance the market by testing these frameworks, while also curbing the illicit trade by offering legal, safe alternatives. These pilots should include strict oversight to ensure compliance and consumer safety, drawing lessons from Canada’s early dispensary trials.
• Mandate Standardized Clinician Training: Develop a national, SAHPRA-endorsed training program for doctors, modelled on Synergy Wellness Academy’s framework but scaled to reach all provinces. Training should cover the endocannabinoid system, clinical prescribing guidelines, Section 21 compliance, and patient counselling. Indemnity support and clear legal protections must accompany this to encourage clinician participation. The UK’s success hinges on trained prescribers operating confidently within a supportive ecosystem—South Africa must replicate this to close the clinician gap.
• Integrate Domestic Production: Connect licensed cultivators to local distribution under Good Manufacturing Practice (GMP) standards. South Africa’s 1,100+ hemp permits and growing medicinal cannabis sector demonstrate production capacity, yet no legal mechanism links cultivators to patients. A domestic supply chain would reduce costs, improve access, and boost the economy. SAHPRA and the Department of Agriculture, Land Reform and Rural Development (DALRRD) should collaborate to define GMP criteria and expedite licensing for local distribution, prioritizing B-BBEE-compliant businesses to ensure inclusivity. Pilot projects could test local supply chains, reducing reliance on illicit markets by channelling licensed products to regulated dispensaries.
• Adopt a Code of Conduct: Establish a national code of conduct for private providers to protect patients and professionals from exploitation. This should outline ethical prescribing practices, transparent pricing, and quality assurance standards. It would prevent predatory practices by unscrupulous providers and build trust in the medical cannabis ecosystem. The code should be enforced by SAHPRA, with penalties for non-compliance, drawing on UK models where private clinics adhere to strict Care Quality Commission (CQC) guidelines.
• Engage Stakeholders Inclusively: Reform must include legacy growers, traditional healers, patients, and township entrepreneurs in policy discussions. The government’s reliance on foreign consultants has sidelined local expertise, undermining cultural and economic relevance. Public consultations should ensure diverse voices shape the framework. Regulated pilot projects could prioritize these stakeholders, fostering economic inclusion while reducing illicit trade through legal market opportunities.
• Prioritize Patient-Cantered Metrics: Establish key performance indicators (KPIs) to measure reform success, such as patient access rates, prescription turnaround times, cost reductions, and reductions in illicit market activity. Regular reporting, modelled on the UK’s Cannabis Industry Council data, would ensure accountability and drive continuous improvement. Patients must be at the heart of reform, with affordability, dignity, and safety as non-negotiable priorities.
The UK’s success proves that a private-sector model with clear regulations can transform patient access and economic outcomes. With our cultivation advantages and patient need, South Africa could lead globally but must act decisively. Regulated pilot projects can pave the way, advancing the market while curbing illicit trade through legal, accessible alternatives.
H3 Legal Solutions remains committed to advocating for a just, inclusive, and medically credible cannabis future. We urge the government to prioritize these reforms with the urgency they demand, ensuring patients, growers, and clinicians are no longer left behind.
